Table 3.
Antibiotic usage in study years 1 and 2
| Agent | Defined daily dosages per 1,000 patient days |
Rate (year 2 vs. year 1) |
95 % CI | |
|---|---|---|---|---|
| Year 1 | Year 2 | |||
| Ceftazidime | 173 | 81 | 0.47 | 0.40–0.55 |
|
All 3rd-generation cephalosporines |
179 | 85 | 0.48 | 0.41–0.55 |
| Ciprofloxacine | 13 | 59 | 4.46 | 3.10–6.59 |
| All fluoroquinolones | 81 | 99 | 1.22 | 1.02–1.46 |
| Piperacillin–tazobactam | 8 | 59 | 7.2 | 4.63–11.76 |
| Amikacin | 207 | 205 | 0.99 | 0.88–1.11 |
| Imipenem | 80 | 48 | 0.60 | 0.48–0.74 |
| Penicillin | 261 | 167 | 0.64 | 0.57–0.71 |
| Metronidazole | 165 | 217 | 1.31 | 1.17–1.48 |